Aureon Prostate PxTM Predicting Prostate Cancer Recurrence

Aureon Laboratories is applying its integrative Systems Pathology platform to develop predictive clinical tests for prostate cancer patients. The initial offering is Prostate Px™, a unique prognostic test designed to provide patients and their physicians with more information as they make decisions about treatment options. Prostate Px is able to stratify patients as high or low risk for disease recurrence. Disease recurrence is defined as one of two endpoints: (1) developing a PSA/biochemical recurrence post prostatectomy and (2) clinical failure (i.e. evidence of bone / soft tissue metastasis, progression through hormonal therapy) within a five year period after having a radical prostatectomy.